{"product_id":"shionogi-bcg-matrix","title":"Shionogi \u0026 Co Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVisual. Strategic. Downloadable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eCurious where Shionogi’s portfolio really sits—market-driving Stars or quietly draining Dogs? Our BCG Matrix preview spots the trends; the full report gives you quadrant-by-quadrant placement, data-backed moves, and tactical recommendations to reallocate capital and boost returns. Skip the guesswork—purchase the complete BCG Matrix for an editable Word report and Excel summary that you can use in meetings today.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnsitrelvir (Xocova) COVID-19 antiviral\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEnsitrelvir (Xocova), approved in Japan in November 2022, sits in a high-growth antiviral need driven by fresh approvals and expanding guidelines through 2023–2024, putting it in a fast lane. Shionogi’s first-to-market advantage in Japan and targeted global launches keep burn high but upside larger. Heavy promotion, ongoing Phase IV data generation, and access deals remain required. If momentum holds as the market normalizes, Xocova can become a dependable cash engine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCefiderocol (Fetroja) for drug‑resistant Gram‑negative infections\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe AMR crisis remains acute—Lancet 2019 analysis attributed 1.27 million deaths to bacterial AMR—driving rising hospital demand for last‑line agents. Fetroja, FDA‑approved in 2019, has a differentiated siderophore cephalosporin mechanism, giving leadership potential within the expanding carbapenem‑resistant niche. Commercializing it is capital‑intensive to educate clinicians, secure formulary placement, and broaden indications. Sustaining share now positions it to become a cash cow as growth stabilizes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBaloxavir marboxil (Xofluza) influenza antiviral\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBaloxavir marboxil (Xofluza), approved in 2018 as a single‑dose oral antiviral, benefits as influenza seasons rebound and single‑dose convenience boosts real‑world uptake. WHO estimates ~1 billion annual influenza infections with 290,000–650,000 respiratory deaths, underpinning market demand. Co‑promotion deals broaden reach in growth markets, but steady promotion and post‑launch surveillance are needed to defend share versus incumbents. With maintained leadership it can mature into a lower‑investment earner.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital anti‑infectives portfolio (select branded injectables)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eStars: hospital anti‑infectives—driven by rising acute‑care volumes and resistance (CDC 2019: ~2.8M antibiotic‑resistant infections annually in the US)—support premium pricing for differentiated injectables; Shionogi’s portfolio, anchored by cefiderocol (Fetroja, FDA approval 2019), sustains strong niche share and robust growth; playbook: outcomes data, stewardship alignment, tight supply to lock leadership before flattening demand.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\u003c\/ul\u003e\n\u003cli\u003eFocus: outcomes evidence, stewardship, supply reliability\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRapid\/targeted infectious‑disease diagnostics tie‑ins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLinking Shionogi therapeutics to rapid, targeted infectious‑disease diagnostics accelerates uptake in high‑growth stewardship settings; 2024 data show targeted diagnostics deliver 24–48 hour faster therapy and up to 30% lower broad‑spectrum antibiotic use, improving drug positioning as ID pathways modernize.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePlatform revenue upside as diagnostics market ≈ $6.4B (2024)\u003c\/li\u003e\n\u003cli\u003eRequires clinical integration investment\u003c\/li\u003e\n\u003cli\u003eEnables multi‑indication stewardship wins\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDifferentiated hospital anti-infectives seize stewardship momentum as diagnostics enable targeted use\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eShionogi Stars: differentiated hospital anti‑infectives (cefiderocol\/Fetroja, Xocova, Xofluza) capture high‑growth stewardship channels amid AMR (Lancet 2019: 1.27M deaths) and US burden (CDC 2019: ~2.8M infections). Diagnostics integration (market ≈ $6.4B in 2024) speeds targeted use and supports premium pricing. Priorities: outcomes evidence, formulary access, supply reliability.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiagnostics market\u003c\/td\u003e\n\u003ctd\u003e$6.4B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAMR deaths (Lancet)\u003c\/td\u003e\n\u003ctd\u003e1.27M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS resistant infections (CDC)\u003c\/td\u003e\n\u003ctd\u003e~2.8M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eBCG Matrix for Shionogi: maps Stars, Cash Cows, Question Marks and Dogs with clear investment, hold or divest recommendations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page Shionogi BCG Matrix relieving portfolio pain, export-ready for slides and C‑suite review.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eViiV HIV royalty stream (e.g., dolutegravir franchise)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHigh‑share, mature dolutegravir franchise within ViiV continues to spin off steady royalties that outpace the incremental cost to support them, reflecting a classic cash cow profile. In 2024 these predictable flows remained a material funding source for Shionogi, underwriting R\u0026amp;D and launch budgets elsewhere. Priority is to maintain partner relationships and protect the long tail of royalties.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy oral antibiotics in Japan (established brands)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegacy oral antibiotics in Japan occupy mature, low-single-digit CAGR markets where prescriber familiarity drives stable volume; promotion is minimal while distribution and supply excellence sustain reach. These established brands deliver healthy economics, with operating margins typically near 20% and consistent free-cash-flow contribution. They are prime candidates to milk for efficiency and cash to fund innovation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMulpleta (lusutrombopag) for thrombocytopenia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMulpleta (lusutrombopag), approved by the US FDA in July 2018 for thrombocytopenia in chronic liver disease patients undergoing invasive procedures, occupies a cash-cow role with a stable indication and repeatable periprocedural demand. Market growth for this segment is modest, yet Mulpleta retains pricing and share through established guideline use and payer coverage. Promotion needs are limited—data refreshes and access efforts—while net revenues support Shionogi funding of higher-risk R\u0026amp;D. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePain\/CNS legacy franchise in Japan\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePain\/CNS legacy franchise in Japan comprises established brands with stable patient flows and mature distribution channels; competitive intensity is moderate and capital investment needs minimal, so operational tweaks (supply-chain optimization, prescribing support) lift margins more than new R\u0026amp;D spend while keeping service high and cash generation steady.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEstablished brands\u003c\/li\u003e\n\u003cli\u003eStable patient flows\u003c\/li\u003e\n\u003cli\u003eMature channels\u003c\/li\u003e\n\u003cli\u003eLow capex, high cash conversion\u003c\/li\u003e\n\u003cli\u003eFocus: margin uplift via ops\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDomestic diagnostics reagents (routine assays)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDomestic diagnostics reagents (routine assays) are commoditized but benefit from sticky hospital and lab contracts, delivering dependable turnover for Shionogi; these lines typically show low single-digit growth (~2% CAGR through 2022–24) while providing stable margins that fund innovation elsewhere. Efficiency and scale drive profit; marketing is minimal beyond account service and KOL relationships. Harvest cash flows while selectively modernizing production and automation to cut costs and sustain competitiveness.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTurnover stability: sticky accounts, repeat purchase-driven\u003c\/li\u003e\n\u003cli\u003eGrowth: low single-digit (~2% CAGR 2022–24)\u003c\/li\u003e\n\u003cli\u003eProfit drivers: scale, operational efficiency\u003c\/li\u003e\n\u003cli\u003eGo-to-market: minimal marketing, focus on account service\u003c\/li\u003e\n\u003cli\u003eStrategy: cash harvest + selective modernization\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh dolutegravir royalties and steady legacy drugs drive 2024 cash flow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigh‑share dolutegravir royalties in 2024 remained a material funding source for Shionogi. Legacy oral antibiotics and Pain\/CNS brands generate stable volume with operating margins near 20%. Mulpleta (FDA Jul 2018) and diagnostics reagents show low single‑digit growth (~2% CAGR 2022–24) and high cash conversion.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2024 note\u003c\/th\u003e\n\u003cth\u003emetric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDolutegravir royalties\u003c\/td\u003e\n\u003ctd\u003eMaterial funding\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOral antibiotics\/Pain\u003c\/td\u003e\n\u003ctd\u003eStable Japan sales\u003c\/td\u003e\n\u003ctd\u003eMargin ~20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMulpleta\u003c\/td\u003e\n\u003ctd\u003eFDA Jul 2018\u003c\/td\u003e\n\u003ctd\u003eStable demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiagnostics reagents\u003c\/td\u003e\n\u003ctd\u003eSticky contracts\u003c\/td\u003e\n\u003ctd\u003e~2% CAGR (22–24)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eShionogi \u0026amp; Co BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the exact BCG Matrix report you'll receive after purchase. No watermarks or demo placeholders—just the fully formatted, ready-to-use document. It's crafted for strategic clarity and market-backed insight, ready to edit, print, or present. Delivery is immediate to your inbox. No surprises, no revisions needed.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56163725345145,"sku":"shionogi-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/shionogi-bcg-matrix.png?v=1762722371","url":"https:\/\/portersfiveforce.com\/products\/shionogi-bcg-matrix","provider":"Porter's Five Forces","version":"1.0","type":"link"}